Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Article Dans Une Revue Epigenomics Année : 2022

Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing

Résumé

Aim: Noninvasive biomarkers such as methylated ccfDNA from plasma could help to support the diagnosis of Alzheimer's disease (AD). Methods: A targeted sequencing protocol was developed to identify candidate biomarkers of AD in methylated ccfDNA extracted from plasma. Results: The authors identified differentially methylated CpGs, regions of which were the same as those identified in previous AD studies. Specifically, a differentially methylated CpG of the LHX2 gene previously identified in a plasma study of AD was replicated in the study. The MBP and DUSP22 regions have been identified in other brain studies of AD and in the authors' study. Conclusion: Although these biomarkers must be validated in other cohorts, methylated ccfDNA could be a relevant noninvasive biomarker in AD.
Fichier non déposé

Dates et versions

cea-04346537 , version 1 (15-12-2023)

Identifiants

Citer

Julien Guemri, Morgane Pierre-Jean, Solène Brohard, Nouara Oussada, Caroline Horgues, et al.. Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing. Epigenomics, 2022, 14 (8), pp.451-468. ⟨10.2217/epi-2021-0491⟩. ⟨cea-04346537⟩
9 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More